Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

NCT06922591 is registered in ClinicalTrials.gov with Tango Therapeutics, Inc. as lead sponsor.

NCT NCT06922591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06922591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
Lead sponsor
Tango Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 31, 2025
Completion date
December 31, 2027
Enrollment
183 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, mtap deletion, nsclc, pancreatic cancer metastatic, pdac, pdac - pancreatic ductal adenocarcinoma, ras mutation, thoracic cancer